Aurum Ventures MKI

Scopio Labs Ltd. is a company based in Tel Aviv, Israel, that specializes in developing advanced digital microscopes utilizing computational imaging technology. Founded in 2015, Scopio Labs focuses on enhancing diagnostics in hematology by providing innovative tools that enable the analysis of blood samples and bone marrow aspirates. Its products are designed to deliver high-resolution imaging and actionable insights from large volumes of data, facilitating new diagnostic methods for blood-related diseases. The company's equipment supports clinical workflows by offering fully digital applications that improve the efficiency and accuracy of cell morphology assessments, thus enabling faster and more reliable detection and diagnosis of conditions such as cancer and other hematological disorders.

KidneyCure Ltd. is a biotechnology company based in Tel Aviv, Israel, focused on developing innovative cell therapies to prevent the progression of Chronic Kidney Disease (CKD). Founded in 2009, the company employs a unique approach that involves administering autologous, revitalized renal progenitor cells to address renal cell depletion. This pioneering method is grounded in research conducted by Professor Benjamin Dekel, a leading authority in nephrology at Sheba Medical Center. KidneyCure's proprietary 3D renal cell cluster technology aims to significantly delay the need for dialysis and transplantation, ultimately improving the quality of life for millions of patients suffering from CKD.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

LifeBond Ltd. is a developer and manufacturer of absorbable bio-surgical medical devices focused on tissue repair, aiming to enhance patient recovery and support the body's natural healing process. Founded in 2006 and based in Caesarea, Israel, the company offers a range of products, including the LifeSeal Surgical Sealant, which provides reinforcement to minimize post-operative complications such as staple-line leakage in various surgical procedures. Another key product, LifeMesh Self-Fixating Mesh, is designed for secure fixation during hernia repair, addressing post-surgical complications effectively. In addition to these products, LifeBond is engaged in the development of tissue adhesives and absorbable hemostats. Their innovative devices are designed to meet a variety of surgical needs and are available in markets including China, the United States, and Europe, although many products remain investigational and have not yet received market approval.

CorAssist Cardiovascular Ltd. is a clinical stage medical device company based in Haifa, Israel, focused on developing innovative products for treating heart failure with preserved ejection fraction and diastolic dysfunction. The company offers CORolla, an elastic self-expanding device designed to be implanted inside the left ventricle through minimally invasive procedures, including transapical and percutaneous approaches. This device enhances cardiac diastolic function by improving diastolic dynamics and filling performance without the need for an external power source. Additionally, CorAssist's ImCardia is a device that attaches to the external surface of the left ventricle and is implanted through a straightforward off-pump procedure, further contributing to the improvement of diastolic function in heart patients. Founded in 2003, CorAssist aims to address the unmet needs in heart failure treatment through its proprietary technology.

BPT is developing and commercializing advanced membranes-based separation solutions addressing the unique needs of the water and wastewater treatment for key industrial processes. BPT patented chemically-stable membrane technology enable customers in the landfill, mining, chemical, biopharma and food industries to comply with the environmental regulations, reuse water and reduce production costs. BPT membranes are field proven to enable lowest cost reclamation of some of the most aggressive and vexing industrial waste water streams.